Schistosomiasis Drug pipeline report- 2020 is an annual R&D review of Schistosomiasis pipeline candidates. The report presents the current status of all major Schistosomiasis therapeutic compounds. Detailed insights into Schistosomiasis pipeline development, current status, companies, drug profiles and Schistosomiasis preclinical and clinical trials are included.
2020 Schistosomiasis Pipeline Market Insights Schistosomiasis disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Schistosomiasis therapies, pipeline by phase and others are included.
Schistosomiasis pipeline Drug profiles- Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.
Schistosomiasis Therapeutic Drug candidates Both active and inactive Schistosomiasis pipeline drug candidates are included in the report
Schistosomiasis Clinical Trials and preclinical Studies Schistosomiasis In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.
Schistosomiasis pipeline market developments Schistosomiasis Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.
Schistosomiasis pipeline companies in active development
The report analyzes Schistosomiasis pipeline of the below companies- Ebelle Pharmaceuticals Inc, Kancera AB, Knight Therapeutics Inc, Merck KGaA, Orygen Biotecnologia SA, Pai Life Sciences Inc, Salvensis, Tongli Biomedical Co Ltd
Report Coverage - What to look out for in 2020 Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included
- Pipeline Snapshot Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others
- Companies 8 Companies investing in Schistosomiasis pipeline from discovery stage to pre-registration phase are included
- Drug profiles Over 10 details of each Schistosomiasis pipeline candidate are included
- Company Profiles Business overview and contact details of all companies operating in the industry are provided
- Market Developments News, Developments and other recent industry developments are included
Our reports have been used by over 10K customers, including:
The analyst presents post–COVID-19 growth opportunities and strategic imperatives for the global decentralized clinical trials (DCT) market, covering the market’s maturity, key participants, adoption drivers and restraints, and recent mergers and acquisitions. The report identifies initiatives by major global contract research organizations...
The ePRO, ePatient diaries, and eCOA market in Asia Pacific is expected to grow from US$ 348.8 million in 2021 to US$ 964.2 million by 2028; it is estimated to grow at a CAGR of 15.6% from 2021 to 2028. Healthcare systems are experiencing a rise in consumer engagement worldwide. In developing countries, health care systems are becoming more...
The ePRO, ePatient Diaries, and eCOA market in Europe is expected to grow from US$ 447.8 million in 2021 to US$ 1,184.3 million by 2028; it is estimated to grow at a CAGR of 14.9% from 2021 to 2028. As per the data provided by Clinicaltrials.gov, 2016 has been a big one for clinical research. There were around 366 thousand clinical studies...
The ePRO, ePatient Diaries, and eCOA market in Middle East and Africa is expected to grow from US$ 48.4 million in 2021 to US$ 112.3 million by 2028; it is estimated to grow at a CAGR of 12.8% from 2021 to 2028. Increasing number of smartphone users is likely to boost the ePRO, e-Patient Diaries, and eCOA’s adoption in the coming years. Mobile-enabled...
The ePRO, ePatient Diaries, and eCOA market in North America is expected to grow from US$ 607.2 million in 2021 to US$ 1,640.6 million by 2028; it is estimated to grow at a CAGR of 15.3% from 2021 to 2028. Increasing number of smartphone users is likely to boost the ePRO, e-Patient Diaries, and eCOA’s adoption in the coming years. As per the...
The ePRO, ePatient Diaries, and eCOA market in South and Central America is expected to grow from US$ 90.3 million in 2021 to US$ 229.0 million by 2028; it is estimated to grow at a CAGR of 14.2% from 2021 to 2028. Patient centricity means designing a treatment, clinical trial, or other health solution centered around the patient. Creating...
Healthcare Contract Research Organization Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Pre-clinical, Clinical), By Service (Clinical Monitoring, Data Management), By Region, And Segment Forecasts, 2021 - 2028
Healthcare Contract Research Organization Market Growth & Trends
The ePRO, epatient diaries, and eCOA market was valued at US$ 1,342.92 million in 2020 and it is projected to reach US$ 4,130.35 million by 2028; it is expected to grow at a CAGR of 15.08% during 2020-2028. Increasing demand for electronic health records (EHRs) and rising use of smartphones are fueling the market growth. However, concerns...
The analyst presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the market’s maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs,...
“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.